Show simple item record

dc.contributor.authorMiddleton, Mark R
dc.contributor.authorLunn, J M
dc.contributor.authorMorris, Charles
dc.contributor.authorRustin, G
dc.contributor.authorWedge, S R
dc.contributor.authorBrampton, M H
dc.contributor.authorLind, Michael J
dc.contributor.authorLee, Siow Ming
dc.contributor.authorNewell, D R
dc.contributor.authorBleehen, N M
dc.contributor.authorNewlands, E S
dc.contributor.authorCalvert, A H
dc.contributor.authorMargison, Geoffrey P
dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-02-12T15:49:39Z
dc.date.available2010-02-12T15:49:39Z
dc.date.issued1998-11
dc.identifier.citationO6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. 1998, 78 (9):1199-202 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid9820180
dc.identifier.urihttp://hdl.handle.net/10541/92028
dc.description.abstractResistance of tumour cells to methylating and monochloroethylating agents in vitro and in vivo has been linked to levels of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). In a clinical trial of temozolomide in advanced malignant melanoma, the relationship between pretreatment MGMT levels in biopsies of cutaneous tumours and involved lymph nodes and clinical response to the drug has been studied. Among 50 evaluable patients, there were three complete responses (CR), four partial responses (PR), six with stable disease (SD) and 37 with progressive disease (PD), with an overall response rate of 14%. In 33 patients in whom MGMT level and clinical response could be evaluated, the tumour MGMT levels (fmol mg(-1) protein) were: CR, 158 +/- 119; PR, 607 +/- 481; NC, 171 +/- 101; PD, 185 +/- 42.3. Thus, measurements of pretreatment levels of MGMT in melanoma did not predict for response to temozolomide.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAntineoplastic Agents, Alkylating
dc.subject.meshBiopsy
dc.subject.meshDacarbazine
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLeukocytes, Mononuclear
dc.subject.meshLymphatic Metastasis
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMiddle Aged
dc.subject.meshO(6)-Methylguanine-DNA Methyltransferase
dc.subject.meshPredictive Value of Tests
dc.subject.meshProspective Studies
dc.titleO6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractResistance of tumour cells to methylating and monochloroethylating agents in vitro and in vivo has been linked to levels of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). In a clinical trial of temozolomide in advanced malignant melanoma, the relationship between pretreatment MGMT levels in biopsies of cutaneous tumours and involved lymph nodes and clinical response to the drug has been studied. Among 50 evaluable patients, there were three complete responses (CR), four partial responses (PR), six with stable disease (SD) and 37 with progressive disease (PD), with an overall response rate of 14%. In 33 patients in whom MGMT level and clinical response could be evaluated, the tumour MGMT levels (fmol mg(-1) protein) were: CR, 158 +/- 119; PR, 607 +/- 481; NC, 171 +/- 101; PD, 185 +/- 42.3. Thus, measurements of pretreatment levels of MGMT in melanoma did not predict for response to temozolomide.


This item appears in the following Collection(s)

Show simple item record